Ever Supreme Bio Technology Co

Ever Supreme Bio Technology Co EBITDA per Employee

The EBITDA per Employee of Ever Supreme Bio Technology Co (6712.TWO) as of Oct 18, 2026 is 54.87 M TWD. In the previous year, EBITDA per Employee was 58.20 M TWD — a change of -5.73% (lower).

EBITDA per Employee

54.87 MTWD

YoY

-5.73%

Last updated:

EBITDA per Employee of Ever Supreme Bio Technology Co is 2025 54.87 M TWD. EBITDA per Employee of Ever Supreme Bio Technology Co was 2024 58.20 M TWD. It decreases by -5.73% lower compared to the previous year.

The Ever Supreme Bio Technology Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-10.94 M TWD
Jan 1, 2019
-16.94 M TWD
Jan 1, 2020
-17.08 M TWD
Jan 1, 2021
49.68 M TWD
Jan 1, 2022
33.08 M TWD
Jan 1, 2023
77.90 M TWD
Jan 1, 2024
58.20 M TWD
Jan 1, 2025
54.87 M TWD
The Ever Supreme Bio Technology Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
54.87 MTWD-5.73%
58.20 MTWD-25.28%
77.90 MTWD+135.52%
33.08 MTWD-33.42%
49.68 MTWD-390.91%
-17.08 MTWD+0.84%
-16.94 MTWD+54.75%
-10.94 MTWD+119.16%
-4.99 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ever Supreme Bio Technology Co Stock analysis

What does Ever Supreme Bio Technology Co do? Ever Supreme Bio Technology Co Ltd is a biotechnology company based in Taichung, Taiwan, operating within the healthcare sector. The company has 8 employees and went public on October 26, 2018. It focuses on the research, development, and sale of stem cell products. The company's website is https://www.ever-supreme.com.tw/. Ever Supreme Bio Technology Co Ltd is engaged in the development of stem cell-based therapies, with specific products including ADCV01, a dendritic cell tumor vaccine currently in Phase II clinical trials in Taiwan. The company also develops UMSC01, a human allogeneic umbilical cord stem cell product intended for the treatment of myocardial infarction. UMSC01 is approved for Phase I clinical trials by the U.S. Food and Drug Administration (FDA) and is undergoing regulatory processes in Taiwan. Additionally, the company is involved in the development of stem cell treatments for acute ischemic stroke, with clinical Phase I trials pending in the United States. The company has plans to expand its product portfolio to include mesenchymal stem cells for multiple sclerosis treatment. Ever Supreme Bio Technology Co Ltd is listed on the Taiwan Stock Exchange under ticker 6712.TWO with ISIN TW0006712003. The company's operations are centered around innovative biotechnology solutions aimed at addressing critical healthcare needs. Ever Supreme Bio Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Supreme Bio Technology Co stock

EBITDA per Employee of Ever Supreme Bio Technology Co is 54.87 M TWD in 2025.

EBITDA per Employee of Ever Supreme Bio Technology Co changed from 58.20 M TWD to 54.87 M TWD, representing a -5.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Ever Supreme Bio Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Ever Supreme Bio Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Ever Supreme Bio Technology Co

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Ever Supreme Bio Technology Co